RxSight (RXST) Net Cash Flow Growth (1y) (2021 - 2026)
RxSight (RXST) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | -562.77% |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 2,827.78% |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 10.50% |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | -395.56% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 168.38% |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | -103.49% |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | -114.85% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -215.59% |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | -54.17% |
| 10 | RxSight | 248.32 Mn | -155.92 Mn | - | -134.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -134.23% |
| Mar 31, 2026 | -121.08% |
| Dec 31, 2025 | -26,952.78% |
| Sep 30, 2025 | -38.66% |
| Jun 30, 2025 | 250.52% |
| Mar 31, 2025 | -50.83% |
| Dec 31, 2024 | 120.81% |
| Sep 30, 2024 | -830.12% |
| Jun 30, 2024 | -262.79% |
| Mar 31, 2024 | 2,886.04% |
| Dec 31, 2023 | -106.05% |
| Sep 30, 2023 | 107.02% |
| Jun 30, 2023 | -107.64% |
| Mar 31, 2023 | 97.25% |
| Dec 31, 2022 | 106.55% |
| Sep 30, 2022 | -156.81% |
| Jun 30, 2022 | 69.67% |
| Mar 31, 2022 | -388.04% |
| Dec 31, 2021 | -2,854.83% |
| Sep 30, 2021 | 5,507.54% |